{"id":"atb-1013","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4211107","moleculeType":"Small molecule","molecularWeight":"365.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Autotaxin is an enzyme that generates lysophosphatidic acid, a lipid mediator involved in inflammation, fibrosis, and immune cell activation. By inhibiting autotaxin, ATB-1013 decreases LPA levels, which may reduce pathological immune responses and fibrotic remodeling in affected tissues. This mechanism has potential applications in autoimmune and fibrotic diseases.","oneSentence":"ATB-1013 is an autotaxin inhibitor that reduces lysophosphatidic acid (LPA) production to modulate immune and fibrotic responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:45.676Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic sclerosis (scleroderma)"}]},"trialDetails":[{"nctId":"NCT05573477","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes","status":"UNKNOWN","sponsor":"Autotelicbio","startDate":"2022-11-16","conditions":"Essential Hypertension, Diabetes Mellitus, Type 2","enrollment":248}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ATB-1013","genericName":"ATB-1013","companyName":"Autotelicbio","companyId":"autotelicbio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATB-1013 is an autotaxin inhibitor that reduces lysophosphatidic acid (LPA) production to modulate immune and fibrotic responses. Used for Systemic sclerosis (scleroderma).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}